Pharmac funds injectable letermovir to prevent CMV

Updated

Written by

Reviewed by Smiths Insurance & KiwiSaver Licensed Financial Advice Provider (FSP712931)

Our editorial process

Read this article with AI:

Photo for the story: Pharmac funds injectable letermovir to prevent CMV

From 1 December 2026, Pharmac will fund injectable letermovir (Prevymis) to help prevent cytomegalovirus infection in severely immunosuppressed patients and stem cell transplant recipients.

The government agency confirmed the move in a 10 November 2026 media release, saying the decision follows earlier funding of the tablet form of letermovir on 1 May 2026.

From 1 December 2026, letermovir Inj 20 mg per ml, 12 ml vial (Prevymis) will be listed in the Herpesvirus Treatment subtherapeutic group of the Infections therapeutic group in part II of section H of the Pharmaceutical Schedule, according to a separate Pharmac decision document.

Pharmac’s Manager Pharmaceutical Funding, Michaela Lion, said the decision to fund letermovir in injectable form follows Pharmac’s decision on 1 May 2026 to fund the treatment in tablet form, as reported by LiveNews.

Clinicians advised Pharmac that relying solely on the tablet formulation could create challenges with accurate dosing for some patients and might not be suitable for patients who have difficulty swallowing tablets, the agency said in its news item.

Lion said CMV is a common virus most people are exposed to in childhood and that it stays in the body for life without causing problems for most people, but can cause serious illness in people whose immune systems are not working properly, particularly those who have had an allo-HSCT.

“We heard from clinicians that some of their patients found it difficult to tolerate the tablet form of letermovir,” Lion said in comments carried by LiveNews.

Pharmac described letermovir as an antiviral medicine used to prevent CMV infection rather than treating it once someone becomes unwell, saying it works by preventing CMV from becoming active.

Clinical advisors told Pharmac that preventing CMV infection can make a meaningful difference for people with weak immune systems, particularly in the early stages of recovery after an allo-HSCT, the agency said.

Pharmac said preventing CMV can help reduce serious illness and complications, avoid long hospital stays and intensive treatment, and support people to recover at home sooner and spend less time away from whānau.

Letermovir in tablet form will remain funded and available for patients alongside the injectable form, and Pharmac said both formulations will be available for use in hospitals and community pharmacies.

For people managing serious illness, hospital-only treatments like this can sit alongside private health insurance, life insurance and trauma cover, while ACC cover and income protection can support lost earnings when someone is too unwell to work.

This story is general information only. It isn't financial advice and doesn't take your circumstances, health or existing cover into account. Policy terms, conditions, exclusions and stand-down periods apply and can change. QuoteHub usually doesn't charge you for advice and may receive commission from insurers; our disclosure statement explains how we're paid.

Sources

Corrections · How we report the news

Wondering whether this affects your cover?

Book a cover review

Free, no obligation. Financial advice is provided by Craig Smith Business Services Limited, trading as Smiths Insurance & KiwiSaver, a licensed Financial Advice Provider (FSP712931). Disclosure statement

Start your free comparison

Compare panel options first. A licensed NZ adviser can then review existing cover or help with an application.

Free, no obligation. Licensed NZ advisers · Craig Smith Business Services Limited, FAP FSP712931.